Adaptimmune Therapeutics PLC (ADAP)
0.59
+0.02
(+3.93%)
USD |
NASDAQ |
Dec 27, 16:00
0.5856
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Cash from Investing (Quarterly): -66.02M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Biodexa Pharmaceuticals PLC | -- |
| Autolus Therapeutics PLC | -9.589M |
| TC BioPharm (Holdings) PLC | -0.0379M |
| Verona Pharma PLC | 0.00 |
| NuCana PLC | 0.025M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -54.45M |
| Cash from Financing (Quarterly) | 25.00M |
| Free Cash Flow | -56.05M |
| Free Cash Flow Per Share (Quarterly) | -0.2146 |
| Free Cash Flow to Equity (Quarterly) | -79.80M |
| Free Cash Flow to Firm (Quarterly) | -54.89M |
| Free Cash Flow Yield | -38.58% |